ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study).
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with first-line antiangiogenic agents. METHODS/PATIENTS: This retrospective multicenter study included patients from 25 centers treated with antiangiogenic therapy without prior exposure to immune checkpoint inhibitors. Clinical and pathological data were obtained from medical records, and PD-L1 expression was centrally assessed in primary tumor samples using the 22C3 pharmDx assay. Survival was analyzed using Kaplan-Meier estimates, log-rank tests, and Cox regression models. Tumor samples were also analyzed by next-generation sequencing using a customized panel.
resultsOf 340 identified patients, 242 (71.2%) were evaluable. The median age was 64 years, and 76.4% were men. International Metastatic RCC Database Consortium risk was favorable in 7.8%, intermediate in 55.4%, and poor in 36.7%. First-line therapy consisted mainly of sunitinib (70.7%) or pazopanib (26.0%). PD-L1 expression was <1% in 84.7% and ≥1% in 15.3% of tumors. Median overall survival was 14.5 months for PD-L1 <1% and 9.7 months for PD-L1 ≥1% (p = 0.0023). In multivariable analysis, PD-L1 ≥1%, poor risk, and >1 metastatic site were independently associated with worse overall survival.
conclusionsPD-L1 expression ≥1% is an independent adverse prognostic factor in mRCC treated with antiangiogenic therapy and may help refine prognostic stratification and treatment planning.
Indexed as
Identifiers
42803874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.